Type 2 diabetes is manifested by impaired insulin secretion in pancreatic beta cells, increased glucagon secretion in alpha cells, and generally has a history of insulin resistance. The treatment of glucose metabolism disorder and the resulting hyperglycemia constitute an important part of the treatment of type 2 diabetes. Glycemic targets can be targeted with A1C <7% to reduce the risk of micro and macrovascular complications in eligible patients, and A1C <6.5% to reduce the risk of diabetic chronic renal failure and retinopathy in those with low risk of hypoglycemia. We can consider the treatment of hyperglycemia in two components; lifestyle changes and glucose-lowering agent therapy.
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Editorial |
Yazarlar | |
Yayımlanma Tarihi | 29 Ocak 2021 |
Gönderilme Tarihi | 20 Ekim 2020 |
Kabul Tarihi | 4 Kasım 2020 |
Yayımlandığı Sayı | Yıl 2021 Cilt: 3 Sayı: 1 |